DNAJB1-PKAc Kinase Is Expressed in Young Patients with Pediatric Liver Cancers and Enhances Carcinogenic Pathways
pubmed.ncbi.nlm.nih.gov shows its articles on its own site.
Read the article on pubmed.ncbi.nlm.nih.gov ↗Article · Dec 2024 · 1 min read
In brief
In brief
This study identifies DNAJB1-PKAc fusion kinase expression in 70% of pediatric hepatoblastoma cases, previously thought exclusive to fibrolamellar carcinoma in adolescents. The fusion kinase drives carcinogenesis by upregulating cell cycle progression genes while suppressing tumor suppressors through β-catenin-mediated pathways.
Written by the GCMD Library team from the article.
Statements in this article
Hepatoblastoma and fibrolamellar hepatocellular carcinoma are the most common liver malignancies in children and young adults.
Fibrolamellar hepatocellular carcinoma oncogenesis is associated with the generation of the fusion kinase DNAJB1-PKAc.
DNAJB1-PKAc has been found in 90% of fibrolamellar hepatocellular carcinoma patients' tumors but not in other liver cancers.
DNAJB1-PKAc is expressed in 70% of hepatoblastoma and hepatocellular carcinoma-NOS patients.
Hepatoblastoma tumors that do not have cells expressing DNAJB1-PKAc show elevated expression of the membrane attack complex, which eliminates cells expressing DNAJB1-PKAc.
Fusion-positive hepatoblastoma and hepatocellular carcinoma-NOS samples have upregulated pathways including genes involved in the G1 to S transition and in liver cancer.
Fusion-positive hepatoblastoma and hepatocellular carcinoma-NOS samples have downregulated pathways including over 60 tumor suppressors, the CYP family, and the SLC family.
The repression of tumor suppressors, CYP family, and SLC family genes involves DNAJB1-PKAc-β-catenin-TCF4-mediated elevation of the HDAC1-Sp5 pathway.
The DNAJB1-PKAc kinase is detected in livers of 1-year-old children.